111. 1996. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med.; 2: 899-905., , , .
112. 2000. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A.; 97: 6820-6825., , , .
113. 2000. Methodological problems in evaluating efficacy of a treatment in multiple sclerosis. Pathol Biol (Paris).; 48: 104-13., .
114. 1997. Growth factors and myelin regeneration in multiple sclerosis. Mult Scler.; 3: 113-20..
115. 1988. Expression of genetically dete mined diabetes and insulitis in the nonobese diabetic (NOD) mouse at the level of bone marrow-derived cells. Transfer of diabetes and insulitis to nondiabetic (NOD X B10) F1 mice with bone marrow cells from NOD mice. J Exp Med.; 167: 1801-10., , , , .
116. 1997. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol.; 76: 15-28., , , .
117. 1995. A combination of BDNF and NT-3 promotes supraspinal axonal regeneration into Schwann cell grafts in adult rat thoracic spinal cord. Exp Neurol.; 134: 261-72., , , , .
118. 1999. “Global” cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain. Proc Natl Acad Sci U S A.; 96: 7029-34., , .
119. 1999. Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-alpha-induced injury. Endocrinology.; 140: 3063-72., .
120. Zhang J, ed. Immunotherapy in Neuroimmunologic Diseases. London, England: Martin Dunitz; 1998., , , , . T-cell vaccination for the treatment of multiple sclerosis. In